The University of Tokyo · Medicine
Professor Taketo Kawai's research lab specializes in urological oncology, with a primary focus on urothelial carcinoma (UC) and prostate cancer. The lab investigates immunotherapeutic strategies, including pembrolizumab and novel targets like heat shock protein 105 (Hsp105), to improve outcomes in advanced and metastatic disease. Key research directions include understanding immune-related adverse events as prognostic biomarkers, optimizing treatment sequencing after immune checkpoint inhibitors, and exploring age-related differences in tumor behavior and treatment response. The lab also examines evolving treatment trends, such as the shift toward radical prostatectomy over androgen deprivation therapy in Japan.
Figures are computed from collected data and may differ slightly.
Even after minimizing immortal time bias by time-dependent analysis, the incidence of irAEs, especially grade 1-2 irAEs, could be a significant predictor of favorable prognoses in patients with UC who have undergone pembrolizumab treatment.
EV and platinum rechallenge showed equivalent oncological outcomes, even after PSM, and both treatments should therefore be effective treatment options for post-platinum, post-pembrolizumab advanced UC.
Testicular germ cell tumors in patients aged ≥50 years are more commonly seminomas, and tend to be diagnosed at earlier stages compared with younger patients; however, the prognosis of older patients is not favorable compared with that of younger patients.
Patients with aUC treated in the recent era exhibited significantly longer survival than those treated before the introduction of pembrolizumab. The improved survival was primarily attributable to the use of pembrolizumab.
Heat shock protein 105 (Hsp105) is one of the cancer/testis antigens, which is overexpressed in a variety of cancer cells, including urinary bladder cancer, and has been investigated as a target molecule for immunotherapy due to its immunogenicity. In this study, we assessed the expression of Hsp105 in primary bladder cancer samples from 84 patients treated with radical cystectomy, using immunohistochemical analysis, and investigated its correlation with clinicopathological characteristics and c
In Japan, RP and RT have increased as initial treatments for prostate cancer, whereas ADT has decreased. Consequently, RP has emerged as the most commonly selected initial treatment, replacing ADT.
PSA doubling time of ≥6 months may be a key indicator of the favorable efficacy of SDT for oligoprogressive CRPC.
Open papers in the app to read, cite, and organize with AI.
